Candice L. C.

Conducts clinical studies on hematologic cancers such as acute leukemias, lymphomas, and multiple myeloma.

• CAR‑T cell approaches in B‑cell acute lymphoblastic leukemia
• Novel agents for relapsed/refractory diffuse large B‑cell lymphoma
• Proteasome inhibitor‑based combos in multiple myeloma
• Risk‑adapted therapy for acute myeloid leukemia

Aims to integrate precision medicine into standard treatment pathways.

Focuses on disease‑modifying interventions for hereditary transthyretin amyloidosis and related cardiomyopathy.

• TTR stabilizer efficacy in ATTR‑CM
• Gene‑silencing therapies for ATTR‑v‑PN
• Cardiac outcome measures in amyloid cardiomyopathy
• Biomarker development for early disease detection

Seeks to translate molecular insights into patient‑centered therapies.

Explores targeted treatments for systemic autoimmune conditions such as systemic lupus erythematosus and vasculitis.

• B‑cell depletion in lupus nephritis
• IL‑6 inhibition in ANCA‑associated vasculitis
• JAK inhibition for active psoriatic arthritis
• Biologic therapy for primary Sjögren’s syndrome

Prioritizes organ‑preserving strategies and reduction of long‑term steroid exposure.

Evaluates novel therapies for cardiovascular risk and kidney disease, including acute coronary syndrome and APOL1‑related nephropathy.

• IL‑6 pathway blockade after myocardial infarction
• SGLT2 inhibitor impact on heart failure with preserved ejection fraction
• APOL1‑targeted agents in proteinuric kidney disease
• Antithrombotic optimization in patients with concurrent antiplatelet therapy

Integrates cardiovascular and renal endpoints to address cardiorenal syndrome.